biostudies-literatureAbrahao RNCATS NIH HHSHealth Resources and Services Administration (HRSA) of the U.S. Department of Health and Human ServicesRich and Weissman Family Lymphoma and Survivorship Fund St. Baldrick’s Research GrantNCIRD CDC HHSNational Center for Advancing Translational Science (NCATS), National Institute of Health1091-1101https://www.ebi.ac.uk/biostudies/studies/S-EPMC9423937biostudies-literatureUnknown63(5)We compared secondary primary malignancy risk (SPM) in HIV-uninfected and HIV-infected Hodgkin lymphoma (HL) survivors. We used data from the California Cancer Registry on patients diagnosed with HL from 1990 to 2015 (all ages included), and standardized incidence ratios (SIRs) and multivariable competing risk models for analyses. Of 19,667 survivors, 735 were HIV-infected. Compared with the general population, the risk of SPM was increased by 2.66-fold in HIV-infected and 1.92-fold in HIV-uninfected survivors. Among HIV-infected survivors, median time to development of SPM was shorter (5.4 years) than in HIV-uninfected patients (8.1 years). Additionally, the highest risk of SPM was observed <2 years after diagnosis in HIV-infected survivors (SIR = 4.47), whereas risk was highest ≥20 years after diagnosis (SIR = 2.39) in HIV-uninfected survivors. The risk of SPMs persisted for decades and was higher among HIV-infected survivors, suggesting that these patients should benefit from long-term surveillance and cancer prevention practices.Leukemia & lymphomaSecond primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors.PMC9423937T32HP30037UL1 TR001860H23 IP000860Kahn JMKeegan THMWun TLi QWBrunson AMAbrahao RfalseSecond primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors.We compared secondary primary malignancy risk (SPM) in HIV-uninfected and HIV-infected Hodgkin lymphoma (HL) survivors. We used data from the California Cancer Registry on patients diagnosed with HL from 1990 to 2015 (all ages included), and standardized incidence ratios (SIRs) and multivariable competing risk models for analyses. Of 19,667 survivors, 735 were HIV-infected. Compared with the general population, the risk of SPM was increased by 2.66-fold in HIV-infected and 1.92-fold in HIV-uninfected survivors. Among HIV-infected survivors, median time to development of SPM was shorter (5.4 years) than in HIV-uninfected patients (8.1 years). Additionally, the highest risk of SPM was observed <2 years after diagnosis in HIV-infected survivors (SIR = 4.47), whereas risk was highest ≥20 years after diagnosis (SIR = 2.39) in HIV-uninfected survivors. The risk of SPMs persisted for decades and was higher among HIV-infected survivors, suggesting that these patients should benefit from long-term surveillance and cancer prevention practices.2022-01-01T00:00:00Z2022 May2025-04-22T03:31:05.965Z2025-04-05T20:46:04.453ZS-EPMC94239373498928310.1080/10428194.2021.2020775